ストックスクリーナーアプリを入手
4.67
9.85%
-0.51
アフターアワーズ：
4.67
前日終値:
$5.18
開ける：
$5.12
24時間の取引高:
1.12M
Relative Volume:
1.17
時価総額：
$280.96M
収益：
-
当期純損益:
$-44.80M
株価収益率:
-6.2267
EPS:
-0.75
ネットキャッシュフロー:
$-30.67M
1週間 パフォーマンス:
-12.05%
1か月 パフォーマンス:
-4.11%
6か月 パフォーマンス:
+16.75%
1年 パフォーマンス:
-10.54%
1日の値動き範囲:
$4.65
$5.205
1週間の範囲:
$4.65
$5.31
52週間の値動き範囲:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
名前
Aldeyra Therapeutics Inc
セクター
電話
781-761-4904
住所
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.67 | 311.64M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-04-27 | 再開されました | H.C. Wainwright | Buy |
| 2021-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-10-30 | 開始されました | Jefferies | Buy |
| 2020-10-16 | 開始されました | BTIG Research | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Outperform |
| 2018-12-04 | 開始されました | Citigroup | Buy |
| 2018-09-26 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Janney | Buy |
| 2018-01-26 | 開始されました | Seaport Global Securities | Buy |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2016-07-01 | 開始されました | Stifel | Buy |
| 2015-07-01 | 開始されました | Canaccord Genuity | Buy |
| 2015-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2015-03-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2014-06-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
Targets Report: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Earnings Recap Report & Weekly Watchlist of Top Performers - Улправда
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Trade Analysis Report & Daily Market Momentum Tracking - ulpravda.ru
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessPrice Action & Community Verified Trade Signals - DonanımHaber
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Asianet Newsable
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug - Sahm
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Transcript : Aldeyra Therapeutics, Inc.Special Call - marketscreener.com
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA - TradingView — Track All Markets
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan
Aldeyra Therapeutics announces PDUFA extension of the new drug application of Reproxalap for the treatment of dry eye disease - marketscreener.com
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Adversity is less terrifying than hope: Aldeyra Therapeutics Inc (ALDX) - setenews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - 28/22 News
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC - MarketBeat
Winners Losers: Will Aldeyra Therapeutics Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - setenews.com
Aldeyra Therapeutics Inc (137.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Aldeyra Therapeutics Inc. stock oversold or undervaluedCEO Change & Smart Allocation Stock Reports - Newser
FDA’s docket holds 16 more PDUFA dates by year-end - biocentury.com
Can Aldeyra Therapeutics Inc. stock deliver surprise earnings beatChart Signals & Long-Term Capital Growth Strategies - moha.gov.vn
Aldeyra Therapeutics Inc (ALDX) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):